Business
EQT Life Sciences backs Kinaset Therapeutics' USD103 million Series B to advance inhaled therapeutic for treatment of respiratory diseases
EQT Life Sciences is pleased to announce that the LSP 7 Fund has invested in Kinaset Therapeutics (the "Company"), a clinical-stage biopharmaceutical company based in Boston, U.S. developing a novel and differentiated inhaled therapeutic to treat serious respiratory diseases.
About this update from Eqt Ab
[{"type":"list","items":[{"val":[{"type":"text","content":"EQT Life Sciences invests in U.S.-based Kinaset Therapeutics – a clinical-stage biopharma company developing a novel and differentiated inhaled therapeutic to treat serious respiratory diseases","length":193,"tagName":"p"}]},{"val":[{"type":"text","content":"Proceeds from the oversubscribed USD 103 million Series B round to help advance frevecitinib – a single-capsule dry powder inhaler delivering therapeutic lung concentrations, with the potential to treat the broad asthma population","length":235,"tagName":"p"}]},{"val":[{"type":"text","content":"EQT Life Sciences' Daniela Begolo to join Kinaset Therapeutics' Board of Directors","length":95,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":523,"olType":false},{"type":"text","content":"BOSTON, Jan. 12, 2026 /PRNewswire/ -- EQT Life Sciences is pleased to announce that the LSP 7 Fund has invested in Kinaset Therapeutics (the "Company"), a clinical-stage biopharmaceutical company based in Boston, U.S. developing a novel and differentiated inhaled therapeutic to treat serious respiratory diseases.","length":329,"tagName":"p"},{"type":"text","content":"The investment was made as part of Kinaset's oversubscribed USD 103 million Series B financing, led by RA Capital Management and Forge Life Science Partners, with participation from new investors EQT Life Sciences, Vivo, Schroders, Willett Advisors, Pictet, and Sixty Degree Capital, as well as existing investors Atlas Venture, 5AM Ventures, and Gimv.","length":356,"tagName":"p"},{"type":"text","content":"Asthma affects millions of patients worldwide, yet a significant proportion remains inadequately controlled on existing therapies. Today's biologic treatments mainly help patients with certain types of inflammation, leaving many with severe asthma without effective options. This has created a clear unmet need for broadly effective, safe, and inhaled anti-inflammatory therapies that can address the full spectrum of asthma disease.","length":437,"tagName":"p"},{"type":"text","content":"Kinaset Therapeutics's Series B will be used to help advance frevecitinib, a novel inhaled dry powder in development for patients with asthma that remains inadequately controlled by standard of care inhaled maintenance therapies. Frevecitinib is an inhaled pan-JAK in...